Perseris Kit is a drug owned by Indivior Inc. It is protected by 10 US drug patents filed from 2018 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 13, 2028. Details of Perseris Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11013809 | Sustained delivery formulations of risperidone compound |
Feb, 2028
(2 years from now) | Active |
| US9186413 | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(2 years from now) | Active |
| US10010612 | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(2 years from now) | Active |
| US9180197 | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(2 years from now) | Active |
| US11712475 | Sustained delivery formulations of risperidone compound |
Feb, 2028
(2 years from now) | Active |
| US10376590 | Sustained delivery formulations of risperidone compound |
Feb, 2028
(2 years from now) | Active |
| US11110093 | Sustained release small molecule drug formulation |
Nov, 2026
(1 year, 6 months from now) | Active |
| US10058554 | Sustained release small molecule drug formulation |
Sep, 2026
(1 year, 5 months from now) | Active |
| US9597402 | Sustained release small molecule drug formulation |
Sep, 2026
(1 year, 5 months from now) | Active |
| US10406160 | Sustained release small molecule drug formulation |
Jun, 2026
(1 year, 2 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Perseris Kit's patents.
Latest Legal Activities on Perseris Kit's Patents
Given below is the list of recent legal activities going on the following patents of Perseris Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical | 02 Aug, 2023 | US11712475 |
| Recordation of Patent Grant Mailed Critical | 01 Aug, 2023 | US11712475 |
| Recordation of Patent eGrant | 01 Aug, 2023 | US11712475 |
| Mail Patent eGrant Notification | 01 Aug, 2023 | US11712475 |
| Email Notification Critical | 01 Aug, 2023 | US11712475 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Aug, 2023 | US11712475 |
| Patent eGrant Notification | 01 Aug, 2023 | US11712475 |
| Electronic Review Critical | 20 Jul, 2023 | US11712475 |
| Email Notification Critical | 13 Jul, 2023 | US11712475 |
| Issue Notification Mailed Critical | 12 Jul, 2023 | US11712475 |
FDA has granted several exclusivities to Perseris Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Perseris Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Perseris Kit.
Exclusivity Information
Perseris Kit holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Perseris Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2021 |
Several oppositions have been filed on Perseris Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Perseris Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Perseris Kit patents.
Perseris Kit's Oppositions Filed in EPO
Perseris Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 17, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP11162857A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08725543A | Oct, 2016 | Lecomte & Partners | Opposition rejected |
| EP11162857A | Apr, 2014 | Generics [UK] Limited | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Perseris Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Perseris Kit's family patents as well as insights into ongoing legal events on those patents.
Perseris Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Perseris Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 13, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Perseris Kit Generic API suppliers:
Risperidone is the generic name for the brand Perseris Kit. 39 different companies have already filed for the generic of Perseris Kit, with Heritage Pharma Avet having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Perseris Kit's generic
Alternative Brands for Perseris Kit
Perseris Kit which is used for treating schizophrenia., has several other brand drugs in the same treatment category and using the same active ingredient (Risperidone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc |
| |||||||||
| Intra-cellular |
| |||||||||
| Janssen Pharms |
| |||||||||
| Otsuka |
| |||||||||
| Otsuka Pharm Co Ltd |
| |||||||||
| Sunovion Pharms Inc |
| |||||||||
| Teva |
| |||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Risperidone. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Risperidone, Perseris Kit's active ingredient. Check the complete list of approved generic manufacturers for Perseris Kit
About Perseris Kit
Perseris Kit is a drug owned by Indivior Inc. It is used for treating schizophrenia. Perseris Kit uses Risperidone as an active ingredient. Perseris Kit was launched by Indivior in 2018.
Approval Date:
Perseris Kit was approved by FDA for market use on 27 July, 2018.
Active Ingredient:
Perseris Kit uses Risperidone as the active ingredient. Check out other Drugs and Companies using Risperidone ingredient
Treatment:
Perseris Kit is used for treating schizophrenia.
Dosage:
Perseris Kit is available in for suspension, extended release form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 90MG | FOR SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |
| 120MG | FOR SUSPENSION, EXTENDED RELEASE | Prescription | SUBCUTANEOUS |